

EscharEx®





Next generation enzymatic therapy for wound care

Targets \$2B market opportunity

De-risked: Based on a validated technology


Chronic Wound Debridement treatments are abundant but sub-optimal



*Source: OW Primary Research (6/2022) | VLU – Venous Leg Ulcers | DFU – Diabetic Foot Ulcer

EscharEx Provides Next-Generation Enzymatic Debridement for Wound Care - **Debridement and granulation tissue formation within a week**

Venous Leg Ulcer



Before



After

Diabetic Foot Ulcer



Before



After

EscharEx

- Investigational drug containing a sterile mixture of proteolytic enzymes
- Debrides chronic wounds in 4-6 daily applications
- Demonstrated superiority over SANTYL in data from Phase II study
- Inline with current treatment workflows and reimbursement landscape
- Easy to use, daily topical application for outpatient setting
- Extended IP protection
- Phase III Initiation H2 2024; R&D collaborations with 3M, Mölnlycke, MIMEDX